Replies to post #255086 on Biotech Values

[Mufaso]

SDGR has an interest in GPCR (Structure Therapeutics). I believe today's rise in SDGR has something to do with GPCR's rise today. Structure's oral small molecule GSBR-1290 is based on a Orforglipron scaffold rather than a Danuglipron Scaffold.